Gilead Sciences Inc (GILD) Stock Price, Quote & News

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 650 574 3000

Fax: 650 522 5853

Website: www.gilead.com

Address:

333 Lakeside Drive, Foster City, United States

Thinkingman91 Aug. 19 at 11:50 AM

$GILD nailed it

0 · Reply

PeterFaley206 Aug. 19 at 9:07 AM

$IBB $OXLC $GILD $HUT IBB provides diversified biotechnology exposure, Oxford Lane benefits from credit-market conditions, Gilead benefits from its pharmaceutical portfolio, and Hut 8 benefits from Bitcoin and data-center infrastructure demand. I'm watching biotech catalysts, credit spreads, drug sales, Bitcoin prices, and power capacity.

0 · Reply

HueySnow252 Aug. 19 at 9:04 AM

0 · Reply

therofl Aug. 19 at 7:24 AM

$GILD lets goo

1 · Reply

Techdamentals Aug. 19 at 3:15 AM

$GILD breakout with improving volume...

0 · Reply

piglet2112 Aug. 19 at 2:12 AM

$GILD hello old friend I’m Back again .

0 · Reply

Johnny_Lever Aug. 19 at 1:26 AM

$GILD

0 · Reply

knash Aug. 18 at 9:20 PM

$GILD rotation into healthcare? Hummmm. Solid day.

0 · Reply

Jblack500 Aug. 18 at 5:15 PM

$VRTX $ELAN $MRK $GILD $HALO ARWR BMY current basket...vrtx recent new position...added to ELAN today. Sell-off after er created opportunity. Multiple insiders made open market buys on 8/7 near this level.

0 · Reply

JFDI Aug. 18 at 2:24 PM

$GILD

0 · Reply

Court rules companies can't import Gilead medications from overseas in blow to AFP health programs

Aug 13, 2026, 11:15 PM EDT - 5 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB JNJ LLY MRK UNH

Aug 4, 2026, 9:41 PM EDT - 14 days ago

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Aug 4, 2026, 5:07 PM EDT - 14 days ago

AHF Crowns Gilead Corporate Welfare King

Aug 4, 2026, 4:31 PM EDT - 14 days ago

Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Gilead Sciences Earnings Call Transcript: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Gilead Sciences Earnings release: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Gilead Sciences Slides: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Gilead Sciences Quarterly report: Q2 2026

Aug 4, 2026, 4:04 PM EDT - 14 days ago

Gilead second-quarter sales rise 8%, beating Wall Street estimates

Aug 4, 2026, 4:01 PM EDT - 14 days ago

Gilead Sciences Announces Second Quarter 2026 Financial Results

Aug 3, 2026, 2:52 PM EDT - 15 days ago

California's highest court rules for Gilead, says drugmakers don't have 'duty to innovate'

Aug 3, 2026, 1:04 PM EDT - 15 days ago

California's highest court rules for Gilead in 'duty to innovate' case

Jul 24, 2026, 6:26 AM EDT - 26 days ago

CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

Jul 21, 2026, 4:05 PM EDT - 4 weeks ago

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Jul 21, 2026, 1:27 PM EDT - 4 weeks ago

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

MRK

Jul 21, 2026, 10:00 AM EDT - 4 weeks ago

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

Jul 21, 2026, 10:00 AM EDT - 4 weeks ago

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

MRK

Jul 14, 2026, 8:48 AM EDT - 5 weeks ago

Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo

Jun 24, 2026, 4:29 PM EDT - 7 weeks ago

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

Jun 24, 2026, 3:42 PM EDT - 7 weeks ago

For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.

AZN

Jun 23, 2026, 7:45 AM EDT - 2 months ago

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

Jun 17, 2026, 12:30 PM EDT - 2 months ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Jun 15, 2026, 4:34 PM EDT - 2 months ago

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Jun 12, 2026, 8:30 AM EDT - 2 months ago

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Jun 11, 2026, 8:30 AM EDT - 2 months ago

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Jun 9, 2026, 1:20 PM EDT - 2 months ago

Gilead Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 4:35 PM EDT - 2 months ago

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

MRK

Jun 8, 2026, 4:30 PM EDT - 2 months ago

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

MRK

Jun 5, 2026, 3:00 AM EDT - 2 months ago

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

Jun 4, 2026, 4:15 PM EDT - 2 months ago

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

Jun 4, 2026, 4:15 PM EDT - 2 months ago

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

Jun 2, 2026, 8:30 AM EDT - 2 months ago

Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

May 28, 2026, 11:00 AM EDT - 2 months ago

Gilead Sciences Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 27, 2026, 2:00 AM EDT - 3 months ago

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)

May 22, 2026, 2:06 PM EDT - 3 months ago

US FDA approves Gilead's drug for deadly liver infection

May 22, 2026, 2:00 PM EDT - 3 months ago

FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

HDV

May 22, 2026, 7:47 AM EDT - 3 months ago

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

May 21, 2026, 5:00 PM EDT - 3 months ago

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

May 21, 2026, 9:30 AM EDT - 3 months ago

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

May 21, 2026, 3:30 AM EDT - 3 months ago

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

May 19, 2026, 11:00 AM EDT - 3 months ago

Gilead Sciences Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 14, 2026, 9:21 PM EDT - 3 months ago

Gilead Prices $3 Billion of Senior Unsecured Notes

May 13, 2026, 8:30 AM EDT - 3 months ago

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

May 12, 2026, 5:20 PM EDT - 3 months ago

Gilead Sciences Transcript: Bank of America Global Healthcare Conference 2026

May 7, 2026, 4:39 PM EDT - 3 months ago

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

May 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Quarterly report: Q1 2026

May 7, 2026, 4:05 PM EDT - 3 months ago

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

May 7, 2026, 4:01 PM EDT - 3 months ago

Gilead Sciences Announces First Quarter Financial Results

May 7, 2026, 7:00 AM EDT - 3 months ago

Gilead Sciences Slides: Investor presentation

May 5, 2026, 2:40 PM EDT - 3 months ago

Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF

May 5, 2026, 6:01 AM EDT - 3 months ago

Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain

May 4, 2026, 5:15 AM EDT - 3 months ago

Can You Sue A Drug Company For Not Inventing Faster?

May 1, 2026, 10:03 AM EDT - 3 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

ABBV BMY GSK LLY

May 1, 2026, 6:00 AM EDT - 3 months ago

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

Apr 30, 2026, 1:00 PM EDT - 3 months ago

Gilead Sciences Transcript: AGM 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Apr 28, 2026, 8:45 AM EDT - 4 months ago

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

ACLX

Apr 27, 2026, 6:15 PM EDT - 4 months ago

AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

Apr 22, 2026, 4:05 PM EDT - 4 months ago

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

Thinkingman91 Aug. 19 at 11:50 AM

$GILD nailed it

0 · Reply

PeterFaley206 Aug. 19 at 9:07 AM

0 · Reply

HueySnow252 Aug. 19 at 9:04 AM

0 · Reply

therofl Aug. 19 at 7:24 AM

$GILD lets goo

1 · Reply

Techdamentals Aug. 19 at 3:15 AM

$GILD breakout with improving volume...

0 · Reply

piglet2112 Aug. 19 at 2:12 AM

$GILD hello old friend I’m Back again .

0 · Reply

Johnny_Lever Aug. 19 at 1:26 AM

$GILD

0 · Reply

knash Aug. 18 at 9:20 PM

$GILD rotation into healthcare? Hummmm. Solid day.

0 · Reply

Jblack500 Aug. 18 at 5:15 PM

0 · Reply

JFDI Aug. 18 at 2:24 PM

$GILD

0 · Reply

Wigglyick Aug. 18 at 2:23 PM

$GILD

1 · Reply

Thinkingman91 Aug. 18 at 2:00 PM

$GILD what did I say

0 · Reply

Thinkingman91 Aug. 18 at 1:40 AM

$GILD why am I the only one here

2 · Reply

Thinkingman91 Aug. 17 at 7:24 PM

$GILD you get 2 weeks of upwards candles

0 · Reply

Thinkingman91 Aug. 17 at 4:10 PM

$GILD bullish engulfment on the weekly you get 2 weeks of up into data

0 · Reply

OnlyFibs Aug. 16 at 3:38 AM

$GILD | Gilead Sciences | Healthcare 💊 Sellers getting fully absorbed on $GILD as price holds its primary volume profile floor right above key multi-month trendline support! 💥 Consistent buyer defense off $131.44 confirms a firm structural base ahead of the $138.36 breakout trigger ⚡ Fundamentals: Premier healthcare operator generating industry-leading cash flow with high-margin oncology and HIV franchise dominance. Technicals: 1w timeframe showing a bullish trendline support hold coiling firm above baseline moving average support 📊 Stochastic RSI crossing upward out of oversold levels. Holding $134.20 keeps buyers in total control. Bull Key Levels: $134.20 🐂 🔥 | Confirm: $138.36 🐂 📈 | Extension: $144.50 🐂 🚀 Bear Key Levels: $131.44 🐻 ⚠️ | Confirm: $128.00 🐻 🚨 | Extension: $110.00 🐻 📉 Stop Loss: $133.10 🛑 Targets: $144.50 / $155.28 💰 🍺 OVERALL: 🐂 BULLISH 🐂 #hovdid

0 · Reply

JuggernautRaider Aug. 15 at 8:59 PM

Digital is here to stay and the blockchain standard can be improved. No more 💩 coin, the governments can have their own ledges soon enough 🏦 $BITC $PFE $BMY $GILD

0 · Reply

BioTechHealthX Aug. 15 at 5:37 PM

$GILD Gilead Sciences, Inc. (NASDAQ: GILD) enters 2026 with a powerful HIV franchise, a $170 CFRA price target and nearly 30% implied upside. Here’s why GILD stock could deserve a much closer look. https://biotechhealthx.com/biotech-news/is-gilead-sciences-gild-a-good-choice-for-long-term-investors/

0 · Reply

efficiency Aug. 15 at 12:59 PM

$GILD Fit to go. Pays a dividend too.

0 · Reply

Thinkingman91 Aug. 14 at 8:30 PM

$GILD calls next week. There is a thinker in the building

0 · Reply

HawkEye828 Aug. 14 at 6:59 PM

$PROK No reason for this to be down...great opportunity to load. This will be a multibagger. No brainer. On target for kidney drug that will save the government in Billions in dialysis. 70 % positive response rate. ProKidney (NASDAQ: PROK) is a clinical-stage biotechnology company founded in 2015 and headquartered in Winston-Salem, North Carolina. It is focused on developing a first-of-its-kind autologous cell therapy named rilparencel (REACT®) designed to preserve kidney function and delay or prevent the need for dialysis in patients with advanced chronic kidney disease (CKD) $LLY ,$AMGN, $VRTX, $GILD

0 · Reply

GoforProMIS Aug. 14 at 6:58 PM

$PMN just fyi new PT from Guggenheim raised to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $NVS $GILD $SNY

0 · Reply

Market Cap	172.25B
Revenue (ttm)	29.44B
Net Income (ttm)	8.51B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	28.90%
Debt to Equity Ratio	2.23

Volume	5,757,000
Avg Vol	7,501,820
Day's Range	N/A - N/A
Shares Out	1.24B
Stochastic %K	97%
Beta	0.32
Analysts	Strong Sell
Price Target	$158.17